Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text: When the DEA rejected a petition to reschedule marijuana in 2016, it cited marijuana's widespread use as evidence of its potential for abuse, without providing quantitative measures of addictiveness relative to other substances.
Simplified Text: In 2016, the DEA rejected a petition to reschedule marijuana, citing its widespread use as evidence of abuse potential without providing quantitative measures of addictiveness relative to other substances.
Confidence Score: 1.000
Claim Maker: The author
Context Type: News Article
Context Details: { "date": "2016", "drug": "marijuana", "organization": "DEA" }
Subject Tags: Policy DEA Marijuana Drug Scheduling
UUID: d24ad318-9b29-4021-a89f-4cf399867326
Vector Index: ✗ No vector
Created: September 30, 2026 at 5:01 AM (2 weeks ago)
Last Updated: September 30, 2026 at 5:01 AM (2 weeks ago)

Original Sources for this Claim (2)

All source submissions that originally contained this claim.

The Way the FDA and DEA Ban Drugs Is Unaccountable and Arbitrary

Completed Analysis

13 claims 🔥

2 weeks ago

https://reason.com/2026/09/29/the-way-the-fda-and-dea-ban-drugs-is-unaccountable-and-arbitrary

A new Government Accountability Office (GAO) report reveals that the FDA and DEA lack clear policies and procedures for drug scheduling decisions. This arbitrary process impacts research and has contributed to the failures of the war on drugs.

Drug Policy DEA FDA Government Accountability Office Controlled Substances Act Drug Scheduling Marijuana Legalization Bureaucracy

Screenshot of https://reason.com/2026/09/30/hazy-federal-criteria-for-classifying-drugs-invite-arbitrary-bureaucratic-judgments

Hazy Drug Classification Criteria Invite Dubious Bureaucratic Judgments

Completed Analysis

10 claims 🔥

1 week ago

https://reason.com/2026/09/30/hazy-federal-criteria-for-classifying-drugs-invite-arbitrary-bureaucratic-judgments

A GAO report notes that the Controlled Substances Act (CSA) does not define "potential for abuse" or "accepted medical use," leading to arbitrary bureaucratic judgments. This lack of clarity has significant criminal justice implications, as seen in the historical treatment of cannabis.

Drug Policy Controlled Substances Act Drug Classification Government Accountability Office DEA FDA Cannabis Reclassification

Similar Claims (5)

Other claims identified as semantically similar to this one.

In 2022, the Biden administration launched an inquiry seeking to reschedule marijuana, a policy which has been continued by the Trump administration. 1.000

Simplified: In 2022, the Biden administration launched an inquiry to reschedule marijuana, a policy continued by the Trump administration.

2 weeks ago
The past 10 years have seen slow but positive movement toward the federal rescheduling and legalization of some drugs, especially marijuana. 1.000

Simplified: Over the past 10 years, there has been slow but positive movement toward federal rescheduling and legalization of some drugs, particularly marijuana.

2 weeks ago
A 2011 study found that 8.9 percent of marijuana users developed a dependence disorder—a low figure when compared to 67.5 percent of nicotine users, 22.7 percent of alcohol users, or 20.9 percent of c... 1.000

Simplified: A 2011 study found that 8.9 percent of marijuana users developed a dependence disorder, compared to 67.5 percent of nicotine users, 22.7 percent of al...

2 weeks ago
Based on an FDA analysis, HHS said cannabis passed its alternative test for "accepted medical use" and, after reconsidering its "potential for abuse," recommended placing it in Schedule III. 0.900

Simplified: Based on an FDA analysis, the Department of Health and Human Services (HHS) stated that cannabis met its alternative "accepted medical use" test and r...

1 week ago
A new report from the Government Accountability Office reveals that federal drug regulators do not have any clear policies or procedures for making scheduling decisions. 1.000

Simplified: A new report from the Government Accountability Office (GAO) reveals that federal drug regulators lack clear policies or procedures for making schedul...

2 weeks ago